Deliver Your News to the World

GPC Biotech to Present at Eighth Annual BIO CEO & Investor Conference in New York City


Martinsried/Munich (Germany), Waltham, Mass. and Princeton, N.J., February 7, 2006 – GPC Biotech AG (Frankfurt Stock Exchange: GPC; TecDAX 30; NASDAQ: GPCB) today announced that the Company will give a corporate presentation and participate in a focus panel session at the upcoming Eighth Annual BIO CEO & Investor Conference in New York, NY.

Bernd R. Seizinger, M.D., Ph.D., Chief Executive Officer of GPC Biotech will participate in a focus panel session, “Cancer: Revisiting Cytotoxics with New Molecules,” on Tuesday, February 14, 2006 at 9:00 AM EST. Dr. Seizinger will also give a company presentation on Wednesday, February 15, 2006 at 10:30 AM EST. The company presentation will be webcast live and will be accessible through the GPC Biotech Web site at A replay will also be available via the Web site. The conference is being held at the Waldorf Astoria hotel in New York, NY.

GPC Biotech AG is a biopharmaceutical company discovering and developing new anticancer drugs. The Company’s lead product candidate – satraplatin – has achieved target enrollment in a Phase 3 registrational trial as a second-line chemotherapy treatment in hormone-refractory prostate cancer. The U.S. FDA has granted fast track designation to satraplatin for this indication, and GPC Biotech has begun the rolling NDA submission process for this compound. GPC biotech is also developing a monoclonal antibody with a novel mechanism-of-action against a variety of lymphoid tumors, currently in Phase 1 clinical development, and has ongoing drug development and discovery programs that leverage its expertise in kinase inhibitors. GPC Biotech AG is headquartered in Martinsried/Munich (Germany). The Company’s wholly owned U.S. subsidiary has sites in Waltham, Massachusetts and Princeton, New Jersey. For additional information, please visit the Company’s Web site at


This news content was configured by WebWire editorial staff. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.